Merck (MRK) Net Income - Minority (2009 - 2012)
Merck (MRK) posted quarterly Net Income - Minority of -$2.4 billion for Q4 2012, down 0.7% YoY from -$2.5 billion in Q1 2012, and down 0.7% sequentially from -$2.4 billion in Q4 2011.
Merck (MRK) Net Income - Minority (2009 - 2012) Analysis & Trends
Merck has disclosed Net Income - Minority across 4 years of filings, most recently posting -$2.4 billion for Q4 2012.
- In Q4 2012, Net Income - Minority fell 0.7% year-over-year to -$2.4 billion; the TTM figure through Dec 2012 stood at -$2.4 billion (down 0.7% YoY), while the FY2012 annual figure was -$2.4 billion, down 0.7% from the prior year.
- Net Income - Minority fell to -$2.4 billion in Q4 2012, from -$2.4 billion in the prior quarter.
- Over the last five years, Net Income - Minority for MRK reached as high as -$2.4 billion in Q4 2011 and fell as low as -$2.5 billion in Q1 2010.
- The 4-year median for Net Income - Minority is -$2.4 billion (2010), against an average of -$2.4 billion.
- Annual changes were most pronounced in 2011 — Net Income - Minority advanced 0.41% — and 2012, when it retreated 0.7%.
- A 4-year view of Net Income - Minority shows it stood at -$2.4 billion in 2009, then dropped by 0.08% to -$2.4 billion in 2010, then gained by 0.12% to -$2.4 billion in 2011, then declined by 0.7% to -$2.4 billion in 2012.
- According to Business Quant data, Net Income - Minority over the past three periods registered -$2.4 billion, -$2.4 billion, and -$2.5 billion for Q4 2012, Q4 2011, and Q1 2011 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -2.44 Bn |
| Dec 31, 2011 | -2.43 Bn |
| Mar 31, 2011 | -2.46 Bn |
| Dec 31, 2010 | -2.43 Bn |
| Sep 30, 2010 | -2.46 Bn |
| Jun 30, 2010 | -2.43 Bn |
| Mar 31, 2010 | -2.47 Bn |
| Dec 31, 2009 | -2.43 Bn |